News

New clinical trial results reveal that intratumoral vidutolimod combined with pembrolizumab shows promise for treating advanced melanoma resistant to PD-1 therapy.

Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) show distinct immune profiles from classic skin conditions.

Dendy Engelman, MD, FACMS, FAAD, explores the benefits of EVERESSE monopolar RF technology, emphasizing safety, comfort, and effective skin rejuvenation.

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about Johnson & Johnson's sBLA for guselkumab structural damage data, insights from LEO Pharma on the recent delgocitinib approval, the FDA's Fast Track designation for rezpegaldesleukin, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dendy Engelman, MD, FACMS, FAAD, explores the latest advancements in laser and energy-based dermatological treatments, including skin resurfacing and body contouring.

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

Whitney Hovenic, MD's new SPOOGE sunscreen hopes to engage Gen Z in sun protection, merging skincare with fun and effective sun care strategies.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

Michael Somenek, MD, shares how a first-of-its-kind Galderma trial using Sculptra and Restylane helped restore volume and skin quality in patients on GLP-1 medications.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of August.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.

Whitney Hovenic, MD, highlights alarming trends in Gen Z's sun protection habits and introduces SPOOGE, a new sunscreen brand promoting skin health.

O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.

The open-label trial showed dusquetide produced similar results to apremilast in reducing oral ulcers, pain, and ulcer duration.

At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections

Explore career transitions in healthcare as PAs Renata Block, DMS-c, MMS, PA-C, and Jessica Dell'Aquila, MS, PA-C, share insights on professional growth and evolving roles in dermatology.

PC111, a novel therapy from Scinai, targets pemphigus vulgaris and SJS/TEN, offering rapid relief without immunosuppression.

VYNE Therapeutics reveals disappointing phase 2b trial results for repibresib gel in nonsegmental vitiligo, missing key efficacy endpoints.

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.